has the potential to optimize parenchymal preservation and potentially yields better functional outcomes than standard partial nephrectomy (SPN). The objective of our study is to compare the surgical precision of SPN and TE for optimizing nephron-mass preservation specifically in the operated kidney and comparing that to functional outcomes. METHODS: Robotic partial nephrectomy patients who had suitable pre-and post-operative imaging studies for analysis of parenchymal mass preservation were included. Of 337 robotic partial nephrectomies performed between 2011 and 2017, 174 met our inclusion criteria. Computed tomography or magnetic resonance imaging were required to be less than 3 months prior and 3-12 months after surgery. Parenchymal mass preservation and surgical precision were estimated for both TE and SPN; precision was defined as actual postoperative parenchymal volume versus predicted postoperative parenchymal volume, presuming a loss of a 5-mm rim of parenchyma in SPN tumor excision and reconstruction. Patient demographics and clinical characteristics were presented as counts and percentages, means and standard deviations, or medians and interquartile ranges overall and by procedure type. Nominal variables were compared by procedure type with chi-square tests or Fishers exact tests. Differences in means and medians were assessed by t-tests and Wilcoxon rank sum tests, respectively. Analyses were performed in SAS 9.4 (Cary, NC).
INTRODUCTION AND OBJECTIVES: Tumor enucleation (TE)
has the potential to optimize parenchymal preservation and potentially yields better functional outcomes than standard partial nephrectomy (SPN). The objective of our study is to compare the surgical precision of SPN and TE for optimizing nephron-mass preservation specifically in the operated kidney and comparing that to functional outcomes. METHODS: Robotic partial nephrectomy patients who had suitable pre-and post-operative imaging studies for analysis of parenchymal mass preservation were included. Of 337 robotic partial nephrectomies performed between 2011 and 2017, 174 met our inclusion criteria. Computed tomography or magnetic resonance imaging were required to be less than 3 months prior and 3-12 months after surgery. Parenchymal mass preservation and surgical precision were estimated for both TE and SPN; precision was defined as actual postoperative parenchymal volume versus predicted postoperative parenchymal volume, presuming a loss of a 5-mm rim of parenchyma in SPN tumor excision and reconstruction. Patient demographics and clinical characteristics were presented as counts and percentages, means and standard deviations, or medians and interquartile ranges overall and by procedure type. Nominal variables were compared by procedure type with chi-square tests or Fishers exact tests. Differences in means and medians were assessed by t-tests and Wilcoxon rank sum tests, respectively. Analyses were performed in SAS 9.4 (Cary, NC).
RESULTS: Analysis included 93 TEs and 81 SPNs. Median age, body mass index, and tumor size were comparable. Precision of excision or reconstruction was 96% for TE vs 90% (IQR [81-97) for SPN (P[0.010). We then compared global renal function in both cohorts 3-12 months following the procedure and found that eGFR in SPN patients decreased whereas in TE patients, eGFR did not decrease and these results are statistically significant (P[0.024).
CONCLUSIONS: Our analysis demonstrates that TE maximally spares normal ipsilateral parenchyma compared to SPN. We also demonstrate that renal function is spared in TE; this suggests that efforts to maximally spare renal parenchyma may lead to better postoperative renal functional outcomes.
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MP31-09 RETROPERITONEAL ROBOT -ASSISTED PARTIAL NEPHRECTOMY: A SINGLE INSTITUTION EXPERIENCE
Manar Malki*, Muddassar Hussain, Neil Barber, Frimley, United Kingdom INTRODUCTION AND OBJECTIVES: Partial nephrectomy is the gold standard treatment for small renal masses. Currently, robotassisted partial nephrectomy (RAPN) is the most common approach. Traditionally, RAPN is performed via the transperitoneal approach in most renal cancer centres. A few institutions have reported on outcomes and safety of retroperitoneal robot-assisted partial nephrectomy. Most of these studies had small number of patients. In this study, we report on surgical outcomes of R-RAPN.
METHODS: From April 2012 to September 2018, 442 patients underwent RAPN, of whom 397 patients had R-RAPN. We reviewed patients' demographic, operative data, peri-operative and postoperative complications, postoperative histology. RESULTS: Two thirds of patients (66.2%) were men. The median age was 60 years (interquartile range [IQR] 52 -69). The mean body mass index (BMI) is 28.5 kg/m2 (IQR 25.1 -31.0). Median maximum tumour diameter was 3.0 cm (IQR 2.0 -3.7). The median R.E.N.A.L nephrometry score is 6 (IQR 5 -8). Almost half (46.6%) of excised tumours were located posteriorly. Median operative time and warm ischaemia time were 129 min (IQR 105.6 -150) and 21 min (IQR 17.2 -26.2) respectively. Median estimated blood loss is 20 mL. The median length of stay (LOS) is 1 day (IQR 1 e 2).
Two cases were converted to open partial nephrectomy and 6 cases were converted to robotic assisted radical nephrectomy (total 2%). 18 patients (4.5%) experienced post-operative complications (! grade 2 Clavien-Dindo classification system). The rate of peri-operative transfusion was 1%.
55% of tumours were reported as clear cell carcinomas (table 1) . 80% of tumours were histologically staged as T1a with six positive margins (1.8%). There are only 3 reported recurrences (0.7%) with median follow-up of 35 months. The rate of achieving Trifecta (negative surgical margin, no postoperative complications and warm ischaemia time of 25 minutes) was 67.3% CONCLUSIONS: Retroperitoneal RAPN represents a valid approach to treat patients with posterior and most anterior small renal masses. R-RAPN is safe, achieves the required trifecta and a very short LOS.
To best to our knowledge, our study represents the world's largest single institution reported study on retroperitoneal RAPN. METHODS: 360 consecutive RAPNs were analyzed from a prospectively-maintained database. We calculated CSA for all renal tumors with the formula proposed by Hsieh et al. (2016) : CSA[ 2*P*r*d, where P z 3.14, r [ tumor radius (cm), and d [ tumor depth (cm). We analyzed patient and tumor characteristics, pathology, and intraoperative/postoperative outcomes and their association with CSA. Patients were excluded if they had prior RAPN (n[7), had RAPN for calyceal diverticulum (n[4), if >1 tumor removed during RAPN (n[9), or if all variables were not available for calculating CSA (n[8) for a final cohort of 332. After adjusting for multiple tests, p 0.017 was considered statistically significant. RESULTS: Median age was 63 years and 132 (39.8%) patients were female. Median CSA was 12.2 cm2. Median warm ischemia time was 18 minutes, median length of stay (LOS) was 2 days, 20 patients (6.0%) had a post-operative complication of Grade III or higher, and median percent change in estimated glomerular filtration rate (eGFR) from preoperative to 1 month after RAPN was -11.4%. Higher CSA was associated with higher warm ischemia time (WIT) (Spearman correlation [rs] [0.52, P<0.001), higher estimated blood loss (EBL) (rs[0.27, P<0.001), and longer LOS (rs[0.24, P<0.001). Higher CSA was also associated with decreased eGFR at post-operative day 1 and 1 month after RAPN when evaluated based on both absolute change and percent change in eGFR from baseline (all P 0.001). The association between CSA and change in eGFR from baseline to 6 month postop was not statistically significant after adjustment for Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e435
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